Quinolines Or Isoquinolines (including Hydrogenated) Patents (Class 514/187)
  • Publication number: 20120135088
    Abstract: A fungicidal composition containing, as active ingredients, (a) a benzoylpyridine derivative represented by the following formula or its salt: wherein X is a halogen atom, a nitro group, a substitutable hydrocarbon group, a substitutable alkoxy group, a substitutable aryloxy group, a substitutable cycloalkoxy group, a hydroxyl group, a substitutable alkylthio group, a cyano group, a carboxyl group which may be esterified or amidated, or a substitutable amino group, n is 1, 2, 3 or 4; R1 is a substitutable alkyl group, R2? is a substitutable alkyl group, a substitutable alkoxy group, a substitutable aryloxy group, a substitutable cycloalkoxy group or a hydroxyl group, p is 1, 2 or 3, and R2? is a substitutable alkoxy group or a hydroxyl group, provided that at least two of R2? and R2? optionally form a condensed ring containing an oxygen atom and (b) at least one other fungicide.
    Type: Application
    Filed: May 26, 2011
    Publication date: May 31, 2012
    Applicant: ISHIHARA SANGYO KAISHA, LTD.
    Inventors: Hisaya NISHIDE, Shigeyuki Nishimura, Shigeru Mitani, Koji Minamida, Fumio Kanamori, Munekazu Ogawa, Shigehisa Kanbayashi, Toyoshi Tanimura, Koji Higuchi, Hidemasa Kominami, Tomohiro Okamoto, Akihiro Nishimura
  • Publication number: 20120135973
    Abstract: The present invention provides analgesic compounds comprising at least one modified metalloporphyrin compound. Also provided are methods of treating pain by orally administering an analgesic compounds comprising at least one modified metalloporphyrin compound.
    Type: Application
    Filed: September 8, 2011
    Publication date: May 31, 2012
    Applicant: SOUTHERN ILLINOIS UNIVERSITY EDWARDSVILLE
    Inventors: Daniela Salvemini, William L. Neumann, Smita Rausaria
  • Patent number: 8158647
    Abstract: Provided herein are substituted pyrrolopyridine heterocycles and substituted pyrazolopyridine heterocycles, pharmaceutical compositions comprising said heterocycles and methods of using said heterocycles in the treatment of disease. The heterocycles disclosed herein function as kinase modulators and have utility in the treatment of diseases such as cancer, allergy, asthma, inflammation, obstructive airway disease, autoimmune diseases, metabolic disease, infection, CNS disease, brain tumor, obesity, asthma, hematological disorder, degenerative neural disease, cardiovascular disease, or disease associated with angiogenesis, neovascularization, or vasculogenesis.
    Type: Grant
    Filed: May 29, 2008
    Date of Patent: April 17, 2012
    Assignee: SGX Pharmaceuticals, Inc.
    Inventors: Jeffrey M. Blaney, Andreas Gosberg, Stefan N. Gradl, Gavin Hirst, Stephanie A. Hopkins, Paul A. Sprengeler, Ruo W. Steensma, Johnny Uy
  • Publication number: 20120022036
    Abstract: A method for treating osteoporosis and related methods are disclosed. The methods generally comprise administering to a patient in need of treatment an effective amount of tris(8-quinolinolato)gallium(III) or an analog thereof.
    Type: Application
    Filed: September 30, 2011
    Publication date: January 26, 2012
    Applicant: NIIKI PHARMA INC.
    Inventor: Hooshmand SHESHBARADARAN
  • Publication number: 20110280959
    Abstract: A fungicidal composition containing, as active ingredients, (a) a benzoylpyridine derivative represented by the following formula or its salt: wherein X is a halogen atom, a nitro group, a substitutable hydrocarbon group, a substitutable alkoxy group, a substitutable aryloxy group, a substitutable cycloalkoxy group, a hydroxyl group, a substitutable alkylthio group, a cyano group, a carboxyl group which may be esterified or amidated, or a substitutable amino group, n is 1, 2, 3 or 4; R1 is a substitutable alkyl group, R2? is a substitutable alkyl group, a substitutable alkoxy group, a substitutable aryloxy group, a substitutable cycloalkoxy group or a hydroxyl group, p is 1, 2 or 3, and R2? is a substitutable alkoxy group or a hydroxyl group, provided that at least two of R2? and R2? optionally form a condensed ring containing an oxygen atom and (b) at least one other fungicide.
    Type: Application
    Filed: May 26, 2011
    Publication date: November 17, 2011
    Applicant: ISHIHARA SANGYO KAISHA, LTD.
    Inventors: Hisaya NISHIDE, Shigeyuki Nishimura, Shigeru Mitani, Koji Minamida, Fumio Kanamori, Munekazu Ogawa, Shigehisa Kanbayashi, Toyoshi Tanimura, Koji Higuchi, Hidemasa Kominami, Tomohiro Okamoto, Akihiro Nishimura
  • Publication number: 20110262356
    Abstract: Luminescent and/or electroactive nanoparticles suitable for MRI (Magnetic Resonance Imaging) and/or PET (Positron Emission Tomography) are prepared by mixing luminescent or electroactive compounds and ethyl oxide/propyl oxide block-copolymers in an organic solvent, which is thereafter evaporated in order to obtain a residue; and by hydrolyzing-condensating tetraalkoxysilanes in an aqueous solution in the presence of the residue; the obtained nanoparticles show no or a negligible release of the luminescent or electroactive compounds and are useful for bio-analytic and bio-medic applications.
    Type: Application
    Filed: July 31, 2009
    Publication date: October 27, 2011
    Applicants: CYANAGEN S.R.L., ALMA MASTER STUDIORUM-UNIVERSITA' DI BOLOGNA
    Inventors: Sara Bonacchi, Ricarrdo Juris, Marco Montalti, Luca Prodi, Enrico Rampazzo, Nelsi Zaccheroni, Leopoldo Della Ciana, Serena Fabbroni, Stafano Grilli, Ettore Marzocchi
  • Publication number: 20110257146
    Abstract: The instant invention describes methods of treating KCNQ related diseases and disorders using organozinc compounds. In certain embodiments, pain is treated using Zinc Pyrithione.
    Type: Application
    Filed: January 25, 2007
    Publication date: October 20, 2011
    Applicant: The johns Hopkins University
    Inventors: Min Li, Haiyan Sun, Qiaojie Xiong
  • Publication number: 20110236471
    Abstract: The subject invention concerns platinum complexes that exhibit antitumor cell and/or antiparasitic activity. The subject invention also concerns the use of platinum complexes of the invention to treat oncological and inflammatory disorders. The platinum complexes of the invention can also be used to treat or prevent infection by a virus or a bacterial or parasitic organism in vivo or in vitro.
    Type: Application
    Filed: June 10, 2011
    Publication date: September 29, 2011
    Applicant: UNIVERSITY OF SOUTH FLORIDA
    Inventors: HEIDI KAY, Jay W. Palmer, Joseph A. Stanko, Said M. Sebti
  • Patent number: 8012954
    Abstract: A chelation complex including 8-hydroxyquinoline and zinc mixed with a carrier demonstrates therapeutic efficacy in treating lesions including cancerous lesions, precancerous lesions, cysts and warts.
    Type: Grant
    Filed: May 16, 2006
    Date of Patent: September 6, 2011
    Assignee: Dermex Pharmaceuticals, LLC
    Inventors: Russel T. Jordan, Carl C. Hanson, Frank S. Potestio
  • Publication number: 20110144079
    Abstract: The present invention relates to the use of ionic liquids as antimicrobial agents, and to the use of antimicrobial compositions comprising an ionic liquid, a film-enhancing composition and a viscosity controlling agent. The invention further relates to methods of disinfecting substrate surfaces, to substrates produced by such methods, and to novel ionic liquid compositions.
    Type: Application
    Filed: April 8, 2009
    Publication date: June 16, 2011
    Inventors: Martyn Earle, Ken Seddon, Manuela Gilea, Gabor Boberly, Brendan Gilmore, Sean Gorman, Martin McLaughlin
  • Publication number: 20110110850
    Abstract: The present invention relates to a transition metal complex represented by Formula (I) or salts thereof, or to a ligand represented by Formula (H) or salts thereof, wherein X represents a transition metal, preferably Pt, and methods for their use and preparation. In particular, the invention relates to compounds which may possess useful therapeutic activity in treating amyloid diseases, and in particular, Alzheimer's disease. The invention also relates to the use of these compounds in methods of therapy, and diagnosis, and the manufacture of medicaments as well as compositions containing these compounds.
    Type: Application
    Filed: December 5, 2008
    Publication date: May 12, 2011
    Applicant: PRANA BIOTECHNOLOGY LTD.
    Inventors: Kevin Jeffrey Barnham, Vijaya Kenche
  • Patent number: 7919486
    Abstract: The invention relates to the use of gallium (III) complexes for the treatment of melanomas.
    Type: Grant
    Filed: August 13, 2008
    Date of Patent: April 5, 2011
    Assignee: Niiki Pharma Inc.
    Inventor: Bernhard Keppler
  • Publication number: 20110044899
    Abstract: A compound of formula (I): in which R1 represents a hydrogen atom, an optionally labelled halogen, a radionuclide or a Sn[(C1-C4)alkyl]3 group, Ar represents an aryl group or a heteroaryl group, R9 represents a hydrogen atom, a (C1-C4) alkyl group or forms together with the group R1—Ar a ring fused with the Ar group, A represents a group of formula (?) or (?): R3 and R4 independently represent a hydrogen atom, a (C1-C6)alkyl group, a (C1-C6) alkenyl group or a group of formula (y): wherein R11 represents an optionally labelled halogen, a radionuclide, an aryl or heteroaryl group optionally substituted by an optionally labelled halogen, a radionuclide, a —NO2 group, a —NR5R6 group, a N+R5R6R7X? group, or a —OSO2R12 group, and their addition salts with pharmaceutically acceptable acids.
    Type: Application
    Filed: January 28, 2009
    Publication date: February 24, 2011
    Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, UNIVERSITE D'AUVERGNE CLERMONT 1, LABORATOIRES CYCLOPHARMA
    Inventors: Jean-Michel Chezal, Frederic Dolle, Jean-Claude Madelmont, Aurelie Maisonial, Elisabeth Miot-Noirault, Nicole Moins, Janine Papon, Bertrand Kuhnast, Bertrand Tavitian, Raphael Boisgard
  • Patent number: 7846919
    Abstract: Oxinates including 8-hydroxyquinoline and a heavy metal are topically applied to epidermal lesions for therapeutic effect. The zinc oxinate compositions are shown to be therapeutically effective against The therapeutic composition demonstrates selective toxicity with a therapeutic index of one-hundred percent on human lung cancer, breast cancer, melanoma, venereal warts, male veruoca warts, lesions produced by human papilloma virus, basal cell carcinoma, solar keratosis, and Kaposi's sarcoma. In veterinary applications where dogs, cats, and horses are the patients, the composition shows a one-hundred percent therapeutic index with selective toxicity against eye cancer, sarcoids, sarcoma, malignant melanoma, rectal adenoma, histiocytoma, and sebaceous adenoma.
    Type: Grant
    Filed: February 10, 1998
    Date of Patent: December 7, 2010
    Assignee: Dermex Pharmaceuticals, LLC
    Inventors: Russel T. Jordan, Carl C. Hanson, Frank S. Potestio
  • Patent number: 7803791
    Abstract: The present invention is directed to a Gyrase inhibitor-protein conjugate; in particular a Gyrase inhibitor-albumin conjugate. The present invention further provides methods of the treatment of inflammatory conditions and tumors. Methods of making and producing a Gyrase inhibitor-protein conjugate are also disclosed.
    Type: Grant
    Filed: January 20, 2006
    Date of Patent: September 28, 2010
    Assignee: Albupharm Heidelberg GmbH & Co. KG
    Inventors: Hannsjörg Sinn, Marcel Mülbaier
  • Publication number: 20100175796
    Abstract: Anti fungal and anti-microbial protection for storage items and protective covers.
    Type: Application
    Filed: January 12, 2010
    Publication date: July 15, 2010
    Inventor: Johannes Blok
  • Patent number: 7608614
    Abstract: Intermediates of the formula QUIN: and methods for their preparation are described. The intermediate compounds are useful for preparing active agents for the treatment of hepatitis C virus (HCV) infection.
    Type: Grant
    Filed: March 6, 2006
    Date of Patent: October 27, 2009
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Carl Alan Busacca, Fabrice Gallou, Nizar Haddad, Azad Hossain, Suresh R. Kapadia, Jianxiu Liu, Chris Senanayake, Xudong Wei, Nathan K. Yee
  • Publication number: 20090123400
    Abstract: The present invention provides compositions and methods for decreasing photosensitivity induced by photodynamic therapy (PDT). The compositions and methods of the present method employ porphyrin complexing molecules as agents for reducing photosensitivity.
    Type: Application
    Filed: March 3, 2006
    Publication date: May 14, 2009
    Inventors: Scott Lundahl, Stuart Marcus
  • Publication number: 20080311189
    Abstract: The invention provides several molybdenum (II) complexes (see classes I and II, FIG. 1) as well as pharmaceutical compositions comprising these compounds, that are useful for treating cancer and describes synthetic methods and intermediates useful for preparing the compounds.
    Type: Application
    Filed: March 18, 2004
    Publication date: December 18, 2008
    Inventors: Marta R.P. Norton Matos, Carlos C. Romao, Claudia Cristina Lage Pereira, Sandra S. Rodrigues, Marcia Mora, Maria Joao Pires Silva, Paula M. Alves, Celso Albuquerque Reis
  • Patent number: 7423049
    Abstract: The present invention relates to inhibitors of p38, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.
    Type: Grant
    Filed: May 8, 2006
    Date of Patent: September 9, 2008
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Francesco Salituro, Vincent Galullo, Steven Bellon, Guy Bemis, John Cochran
  • Patent number: 7410959
    Abstract: A pharmaceutical composition includes, as an active ingredient, a compound according to formula 1436 as shown in FIG. 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient. Various pharmaceutical products may be produced including this pharmaceutical composition. Such pharmaceutical products may be used for the treatment of obesity or diabetes. Methods for using the pharmaceutical compositions also are described. In these methods, various diseases are treated or other body functions are activated or inhibited by administering an effective amount of the pharmaceutical composition. For example, diabetes and obesity may be treated by administering an effective amount of the pharmaceutical compositions. Weight gain, and growth factor production can be inhibited by administering an effective amount of these pharmaceutical compositions.
    Type: Grant
    Filed: July 13, 2000
    Date of Patent: August 12, 2008
    Assignee: Genaera Corporation
    Inventors: Michael Zasloff, Jon Williams, William Kinney, Mark Anderson, Michael McLane
  • Patent number: 7375215
    Abstract: A tetrakis(hydroxyphenyl)chlorin, bacteriochlorin or isobacteriochlorin, derivatised at one or more of the hydroxy groups by addition reaction with a diisocyanate, diisothiocyanate or isocyanate-isothiocyanate at one isocyanate or isothiocyanate group thereof, the other isocyanate or isothiocyanate group being itself derivatised by addition reaction with the hydroxy group of an w-alkylated or acylated poly(alkylene oxide) or to a hydroxy group of a link residue itself carrying a residue of such poly(alkylene oxide).
    Type: Grant
    Filed: March 8, 2001
    Date of Patent: May 20, 2008
    Assignee: Bioscience Technology Investment Holdings Limited
    Inventors: Paul Bradley, Mehar Manku
  • Patent number: 7102008
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein the variables A, R1, R2, R3, R4, Z, U, X, Y, Za, and n are defined are as defined herein, which are useful as inhibitors of matrix metalloproteinases (MMP) and/or TNF-? converting enzyme (TACE), or a combination thereof.
    Type: Grant
    Filed: July 31, 2003
    Date of Patent: September 5, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventor: Thomas P. Maduskuie
  • Patent number: 7091351
    Abstract: The invention provides methods for treating cancer and compounds that are useful for the treatment of tumors, as well as pharmaceutical compositions comprising the compounds, and synthetic methods and intermediates useful for preparing the compounds.
    Type: Grant
    Filed: May 28, 2004
    Date of Patent: August 15, 2006
    Assignee: Parker Hughes Institute
    Inventors: Yanhong Dong, Phalguni Gosh, Fatih M. Uckun
  • Patent number: 7078059
    Abstract: The invention provides a method for enhancing bone formation, inhibiting osteoclastic differentiation and/or activating osteoblastic differentiation whereby to manage, treat or achieve prophylaxis of bone disease which comprises administering to a human or animal subject suffering from, or susceptible to bone disease a therapeutically or prophylactically effective amount of a lanthanum compound.
    Type: Grant
    Filed: June 26, 2001
    Date of Patent: July 18, 2006
    Assignee: Shire Holdings AG
    Inventors: Nigel D. Atherton, Joseph William Totten, Michael David Gaitonde
  • Patent number: 7060696
    Abstract: A chelation complex including 8-hydroxyquinoline and zinc mixed with a carrier demonstrates therapeutic efficacy in treating lesions including cancerous lesions, precancerous lesions, cysts and warts.
    Type: Grant
    Filed: September 18, 2002
    Date of Patent: June 13, 2006
    Assignee: Dermex Pharmaceuticals, LLC
    Inventors: Russel T. Jordan, Carl C. Hanson, Frank S. Potestio
  • Patent number: 6878388
    Abstract: Vanadium compounds useful to prevent and/or inhibit adhesion, migration, and invasion of proliferative cells into surrounding tissue.
    Type: Grant
    Filed: November 15, 2000
    Date of Patent: April 12, 2005
    Assignee: Parker Hughes Institute
    Inventors: Fatih M Uckun, Rama Krishna Narla
  • Patent number: 6867217
    Abstract: The invention relates to substituted polycyclic aryl and heteroaryl pyridone compounds useful as inhibitors of serine proteases of the coagulation cascade and compounds, compositions and methods for anticoagulant therapy for the treatment and prevention of a variety of thrombotic conditions including coronary artery and cerebrovascular diseases.
    Type: Grant
    Filed: May 18, 2000
    Date of Patent: March 15, 2005
    Assignee: Pharmacia Corporation
    Inventors: Michael S. South, Qingping Zeng, Ashton T. Hamme, II, Melvin L. Rueppel
  • Patent number: 6809091
    Abstract: A method for the manufacture of a substance having an apoptosis-inducing ability characterized in including a step of subjecting at least one compound selected from the following (a), (b), (c) and (d) [excluding uronic acid and/or uronic acid derivatives; and compounds which contain uronic acid and/or uronic acid derivatives] to a heating treatment: (a) pentose; (b) pentose derivatives; (c) compounds containing pentose; (d) compounds containing pentose derivatives.
    Type: Grant
    Filed: June 28, 2000
    Date of Patent: October 26, 2004
    Assignee: Takara Bio Inc.
    Inventors: Yoko Tatsumi, Hiroaki Sagawa, Hiromu Ohnogi, Eiji Kobayashi, Hua-Kang Wu, Nobuto Koyama, Katsushige Ikai, Ikunoshin Kato
  • Patent number: 6800649
    Abstract: The invention provides a method for inhibiting c-jun activation in mammalian or avian cells comprising contacting the cells with a substance that inhibits the activity of Janus family kinase 3 (JAK-3). The invention also provides a therapeutic method for preventing or treating a pathological condition in a mammal wherein c-jun activation is implicated and inhibition of its activation is desired comprising administering to a mammal in need of such therapy, an effective amount of a substance that inhibits the activity of JAK-3. Novel compounds that are JAK-3 inhibitors, as well as pharmaceutical compositions comprising the compounds are also provided.
    Type: Grant
    Filed: June 30, 1999
    Date of Patent: October 5, 2004
    Assignee: Parker Hughes Institute
    Inventor: Fatih M. Uckun
  • Patent number: 6777405
    Abstract: Duplex polynucleotides containing damage or errors are detected with hindered intercalating compounds which are capable of intercalating only in the presence of such damage or error. Conditions characterized by the presence of polynucleotide errors or damage are treated with such compounds that are capable of catalyzing polynucleotide cleavage with light.
    Type: Grant
    Filed: September 3, 2002
    Date of Patent: August 17, 2004
    Assignee: California Institute of Technology
    Inventors: Jacqueline K. Barton, Brian A. Jackson, Brian P. Hudson
  • Patent number: 6774124
    Abstract: A chelation complex including 8-hydroxyquinoline and zinc mixed with a carrier is effective in treating the bite of the brown recluse spider.
    Type: Grant
    Filed: September 18, 2002
    Date of Patent: August 10, 2004
    Assignee: Dermex Pharmaceuticals, LLC
    Inventors: Russel T. Jordan, Carl C. Hanson, Frank S. Potestio
  • Publication number: 20040147550
    Abstract: This invention provides a class of androgen receptor targeting agents (ARTA). The agents define a new subclass of compounds, which are selective androgen receptor modulators (SARM). Several of the SARM compounds have been found to have an unexpected androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. Other SARM compounds have been found to have an unexpected antiandrogenic activity of a nonsteroidal ligand for the androgen receptor.
    Type: Application
    Filed: October 14, 2003
    Publication date: July 29, 2004
    Inventors: James T. Dalton, Duane D. Miller, Igor Rakov
  • Patent number: 6753317
    Abstract: A compound of formula: comprising the Dmt-Tic pharmacophore and related compositions and methods of use in the inhibition of the binding of an opioid receptor-binding compound with a P-glycoprotein, specifically hMDR-1, are provided.
    Type: Grant
    Filed: March 22, 2001
    Date of Patent: June 22, 2004
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Lawrence H. Lazarus, Severo Salvadori
  • Patent number: 6743786
    Abstract: The invention provides methods for treating cancer and compounds that are useful for the treatment of tumors, as well as pharmaceutical compositions comprising the compounds, and synthetic methods and intermediates useful for preparing the compounds.
    Type: Grant
    Filed: May 8, 2002
    Date of Patent: June 1, 2004
    Assignee: Parker Hughes Institute
    Inventors: Fatih M. Uckun, Yanhong Dong, Phalguni Gosh
  • Patent number: 6689771
    Abstract: The present application describes novel amides and derivatives thereof of formula I: or pharmaceutically acceptable salt forms thereof, wherein these compounds are useful as inhibitors of matrix metalloproteinases, TNF-&agr;, and aggrecanase.
    Type: Grant
    Filed: February 12, 2002
    Date of Patent: February 10, 2004
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Jingwu Duan, Carl P. DeCicco, David J. Nelson, Chu-Biao Xue
  • Patent number: 6685958
    Abstract: The present invention relates to the use of quinolone carboxylic acid formulations in the treatment of ocular and periocular infections. The present invention also relates to sustained release compositions comprising specific quinolone carboxylic acid compounds. The invention also relates to quinolone carboxylic acid compositions and methods of preparing the same.
    Type: Grant
    Filed: April 25, 2001
    Date of Patent: February 3, 2004
    Assignees: InSite Vision Incorporated, SSP Co., Ltd.
    Inventors: Samir Roy, Santosh Kumar Chandrasekaran, Katsumi Imamori, Takemitsu Asaoka, Akihiro Shibata, Masami Takahashi, Lyle M. Bowman
  • Patent number: 6667339
    Abstract: Vanadium (IV) complexes containing a substituted or unsubstituted catecholate ligand, and the spermicidal activity of such compounds. Preferred compounds are vanadocene (IV) complexes containing alkyl substituted catecholate ligands.
    Type: Grant
    Filed: July 23, 2002
    Date of Patent: December 23, 2003
    Assignee: Parker Hughes Institute
    Inventors: Phalguni Ghosh, Faith M. Uckun, Osmond D′Cruz
  • Publication number: 20030162761
    Abstract: The present invention relates to pharmaceutical compositions and formulations comprising a novel class of androgen receptor targeting agents (ARTA) which demonstrate androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor.
    Type: Application
    Filed: October 15, 2002
    Publication date: August 28, 2003
    Inventors: Mitchell S. Steiner, Karen A. Veverka, James T. Dalton, Duane D. Miller
  • Publication number: 20030113381
    Abstract: A chelation complex including 8-hydroxyquinoline and zinc mixed with a carrier demonstrates therapeutic efficacy in treating lesions including cancerous lesions, precancerous lesions, cysts and warts.
    Type: Application
    Filed: September 18, 2002
    Publication date: June 19, 2003
    Inventors: Russel T. Jordan, Carl C. Hanson, Frank S. Potestio
  • Patent number: 6534493
    Abstract: &agr;- and &bgr;-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.
    Type: Grant
    Filed: October 24, 2000
    Date of Patent: March 18, 2003
    Assignee: G.D. Searle
    Inventors: Michael L. Vazquez, Richard A. Mueller, John J. Talley, Daniel Getman, Gary A. DeCrescenzo, John N. Freskos
  • Patent number: 6475505
    Abstract: Concentrates of various classical biocides in a polyester carrier resin when incorporated into a substrate resin, preferably a polyolefin such as polypropylene or polyethylene, provide the substrate polymer which biocidal activity with superior resistance to discoloration (yellowing) than when the biocide is directly incorporated into the substrate polymer as a powder at the same total concentration.
    Type: Grant
    Filed: December 20, 1999
    Date of Patent: November 5, 2002
    Assignee: Ciba Specialty Chemicals Corporation
    Inventor: Urs Stadler
  • Patent number: 6476014
    Abstract: Oxinates including 8-hydroxyquinoline and a heavy metal are topically applied to epidermal lesions for therapeutic effect, wherein said epithelial lesions selected from the croup consisting of cancerous lesions, precancerous lesions, cysts and warts; and permitting said composition to destroy said lesion.
    Type: Grant
    Filed: January 2, 2001
    Date of Patent: November 5, 2002
    Assignee: Dermex Pharmaceuticals, LLC
    Inventors: Russel T. Jordan, Carl C. Hanson, Frank S. Potestio
  • Patent number: 6465450
    Abstract: Vanadium (IV) complexes containing a substituted or unsubstituted catecholate ligand, and the spermicidal activity of such compounds. Preferred compounds are vanadocene (IV) complexes containing alkyl substituted catecholate ligands.
    Type: Grant
    Filed: September 19, 2001
    Date of Patent: October 15, 2002
    Assignee: Parker Hughes Institute
    Inventors: Phalguni Ghosh, Fatih M. Uckun, Osmond D'Cruz
  • Patent number: 6444661
    Abstract: Duplex polynucleotides containing damage or errors are detected with hindered intercalating compounds which are capable of intercalating only in the presence of such damage or error. Conditions characterized by the presence of polynucleotide errors or damage are treated with such compounds that are capable of catalyzing polynucleotide cleavage with light.
    Type: Grant
    Filed: November 23, 1999
    Date of Patent: September 3, 2002
    Assignee: California Institute of Technology
    Inventors: Jacqueline K. Barton, Brian A. Jackson, Brian P. Hudson
  • Patent number: 6432941
    Abstract: The invention provides methods for treating cancer and vanadium compounds that are useful for the treatment of tumors, as well as pharmaceutical compositions comprising the compounds, and synthetic methods and intermediates useful for preparing the compounds.
    Type: Grant
    Filed: August 20, 1999
    Date of Patent: August 13, 2002
    Assignee: Parker Hughes Institute
    Inventors: Fatih M. Uckun, Yanhong Dong, Phalguni Gosh
  • Patent number: 6410592
    Abstract: The present invention relates to aminomethylcarboxylic acid derivatives general formula (I), wherein Z is (CH2)n, O, S, SO, SO2 or N—R5; n is 0, 1 or 2; X represents 1-3 substituents independently selected from hydrogen, halogen, (C1-6)alkyloxy, (C3-6)cycloalkyloxy, (C6-12)aryloxy, (C6-12)aryl, thienyl, SR6, SOR6, SO2R6, NR6R6, NHR6, NH2, NHCOR6, NSO2R6, CN, COOR6 and (C1-4)alkyl, optionally substituted with halogen, (C6-12)aryl, (C1-6)alkyloxy or (C6-12)aryloxy; or 2 substituents at adjacent positions together represent a fused (C5-6)aryl group, a fused (C5-6)cycloalkyl ring or O—(CH2)m—O; m is 1 or 2; Y represents 1-3 substituents independently selected from hydrogen, halogen, (C1-4)alkyloxy, SR6, NR6R6 and (C1-4)alkyl, optionally substituted with halogen; R1 is COOR7 or CONR8R9; R2 and R6 are (C1-4)alkyl; R3, R4 and R5 are independently hydrogen or (C1-4)alkyl; R7, R8 and R9 are independently hydrogen, (C1-4)alkyl, (C6-12)aryl or arylalkyl; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 25, 2001
    Date of Patent: June 25, 2002
    Assignee: Akzo Nobel N.V.
    Inventors: S. G. Gibson, D. R. Jaap, S. N. Thorn, R. R. Gilfillan
  • Patent number: 6350740
    Abstract: The invention provides a method for enhancing the water solubility of cytotoxic trans-platinum complexes. The present invention also provides a method for killing tumor cells, and a method for the treatment of tumors by the administration of a cytotoxic platinum coordination complex of the general formula SP4-2-[PtX(L)(L′)(B)]+.
    Type: Grant
    Filed: September 5, 2000
    Date of Patent: February 26, 2002
    Assignee: Virginia Commonwealth University
    Inventor: Nicholas Farrell
  • Patent number: 6329360
    Abstract: The hetero-linked phenylglycinolamides are prepared by reaction of the corresponding hetero-linked phenylacetic acids with appropriate phenylglycinols. The hetero-linked phenylglycinolamides are suitable as active compounds in medicaments.
    Type: Grant
    Filed: September 18, 2000
    Date of Patent: December 11, 2001
    Assignee: Bayer Aktiengesellschaft
    Inventors: Siegfried Goldmann, Ulrich Müller, Richard Connell, Hilmar Bischoff, Dirk Denzer, Rudi Grützmann, Martin Beuck
  • Patent number: 6306846
    Abstract: Disclosed herein are anti-inflammatory and anti-ulcer copper coordination compounds and a process for using them in the treatment of arthritis and gastrointestinal ulcers in animal bodies. The copper coordination compounds utilized are the reaction products of copper salts with: 1. aromatic carboxylic acids or their alkaline earth salts; 2. heterocyclic carboxylic acids or their alkaline earth salts; 3. amino acids or their alkaline earth salts; 4. amines; and 5. suitably substituted steroids. The process disclosed comprises administering to experimental animals, orally or parentrally (subcutaneously), in controlled dosages, the aforementioned copper coordination compounds for the treatment of inflammation (i.e., arthritis) and ulcers of the gastrointestinal tract.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 23, 2001
    Inventor: John R. J. Sorenson